Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy. Of those, 40 percent also harbor mutations in the PIK3CA gene, and are targeted by the PI3K-alpha inhibitor alpelisib (Novartis' Piqray). However, intrinsic and adaptive drug resistance is the norm with these agents and mechanisms of resistance are still largely unknown in the clinic.
In this webinar, Guotai Xu of Memorial Sloan Kettering Cancer Center will discuss results of CRISPR/Cas9 screens that he has run which suggest endocrine therapy and PI3K-alpha inhibitor resistance occurs and may provide a basis to develop resistance therapeutic strategies to prevent or revert this resistance. Dr. Xu will share details of work in this area that was published in Nature in January 2020.